Navigation Links
Oclaro Announces Second Quarter Fiscal Year 2013 Financial Results
Date:1/31/2013

SAN JOSE, Calif., Jan. 31, 2013 /PRNewswire/ -- Oclaro, Inc. (NASDAQ: OCLR), a provider of optical components, modules and subsystems, today announced the financial results for its second quarter of fiscal year 2013, which ended December 29, 2012.

"Our financial results for the second quarter of fiscal 2013 demonstrate the progress we are making after the merger," said Alain Couder, chairman and CEO. "Our revenues were at the top-end of guidance and we have successfully executed to the planned synergies on schedule. We also took action to strengthen our balance sheet.  Looking ahead, market and economic conditions remain uncertain in a typically softer March quarter. As a result, our efforts will remain focused on reducing operating expenses and improving margin, as well as capitalizing on our new product introductions and strong customer relationships to maximize revenues."

Results for the Second Quarter of Fiscal 2013:Oclaro closed its merger with Opnext, Inc. on July 23, 2012. The financial results for the second quarter of fiscal 2013 include a full quarter of operating results of Opnext. The financial results for the first quarter of fiscal 2013 include approximately ten weeks of operating results of Opnext since the closing of the merger. Results for the second quarter of fiscal 2012 were pre-merger Oclaro and do not include the operating results of Opnext.

  • Revenues were $159.5 million for the second quarter of fiscal 2013, compared with revenues of $148.8 million in the first quarter of fiscal 2013. Pro forma combined revenues for the first quarter of fiscal 2013, including Opnext for the full quarter, were $160.2 million.
  • GAAP gross margin was 13% for the second quarter of fiscal 2013, compared with a GAAP gross margin of 12% in the first quarter of fiscal 2013.
  • Non-GAAP gross margin was 15% for the second quarter of fisca
    '/>"/>

  • SOURCE Oclaro, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related medicine technology :

    1. Oclaro Announces Fourth Quarter and Fiscal Year 2012 Financial Results
    2. KaloBios Pharmaceuticals Announces Pricing of Initial Public Offering
    3. CryoLife Announces Release Date and Teleconference Call Details for 2012 Fourth Quarter and Year End Financial Results
    4. Blue Belt Technologies Announces First U.S. Sale of NavioPFS Surgical System
    5. IDEV Announces Results from Revascularization with Supera on Real World Patients (RESTORE) Study, Demonstrating Positive Clinical Outcomes in Significantly Diseased Patients with Long Lesions
    6. Vanda Announces Phase IIb/III Clinical Study In Major Depressive Disorder Did Not Meet The Primary Endpoint
    7. Targovax AS Announces First Patient Included in Phase I/II Clinical Study With the Therapeutic Cancer Vaccine TG01 in Operable Pancreatic Cancer
    8. Kemwell Announces Successful Pre-NDA US FDA Inspection
    9. Cell Therapeutics Announces Data Safety and Monitoring Board Recommendation to Continue the GOG-0212 Phase 3 Clinical Trial of OPAXIOTM as Maintenance Therapy in Ovarian Cancer
    10. Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common Stock
    11. Vanish Announces Tattoo Removal Giveaway for Valentines Day
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/31/2015)... ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP ... 225mg and 300mg oral tablets, indicated for use in ... for Propafenone Hydrochloride 150mg, 225mg and 300mg tablets was ... Arthur S. Przybyl , President and Chief Executive ... of our fourth product from the portfolio of approved ...
    (Date:3/31/2015)... -- Biorasi , a full-service CRO powered ... Medidata , the leading global provider of ... Offering therapeutic expertise in a number of areas, ... capture (EDC), management and reporting system, Medidata Rave®, ... clinical trial business. ...
    (Date:3/31/2015)... 31, 2015  Cindy Dellecker, former Senior Vice President of ... has accepted a position on the TruHearing Advisory Board. ... care to TruHearing and will act as an advisor ... "Hearing healthcare has always been an important ... personal level," said Dellecker.  "I,m excited to be on ...
    Breaking Medicine Technology:ANI Pharmaceuticals Announces the Launch of Propafenone Tablets 2ANI Pharmaceuticals Announces the Launch of Propafenone Tablets 3Biorasi Selects Medidata's Cloud-Based Platform for Optimal Trial Operations 2Biorasi Selects Medidata's Cloud-Based Platform for Optimal Trial Operations 3Biorasi Selects Medidata's Cloud-Based Platform for Optimal Trial Operations 4TruHearing Announces Addition of Cindy Dellecker to Advisory Board 2
    ... YORK, March 9 /PRNewswire-Asia-FirstCall/ -- American Oriental,Bioengineering, ... China-based pharmaceutical company,dedicated to improving health through ... range of prescription and over the counter ... initiating a phase one clinical,trial of AOBO-001, ...
    ... Association (AMA) Foundation announced today the 28 recipients of the 2009 Seed ... to medical students, physician residents and fellows to conduct basic science, applied ... in the following four categories: , , ... HIV/AIDS , ...
    Cached Medicine Technology:American Oriental Bioengineering to Initiate a Phase One Clinical Trial in the United States of AOBO-001 Oral Capsule 2American Oriental Bioengineering to Initiate a Phase One Clinical Trial in the United States of AOBO-001 Oral Capsule 3AMA Foundation Announces Seed Grant Research Recipients 2AMA Foundation Announces Seed Grant Research Recipients 3
    (Date:3/31/2015)... Illinois (PRWEB) March 31, 2015 ... Visio Stencils Device Library for documenting and diagramming ... following Visio Stencils: , Manufacturer / Device ... PowerEdge r720, Dell PowerEdge r520, Dell PowerEdge r630, ... Power 8 Series, EMC VMAX 100K, VMAX 200K, ...
    (Date:3/31/2015)... Indiana (PRWEB) March 31, 2015 ... DeRose in Youngstown, Ohio in 1987. This ... the curve with not just customer satisfaction, but ... been added to the well-stocked arsenal of Yesco ... by American Green Technology® (AGT). The patented environmental ...
    (Date:3/31/2015)... 31, 2015 Burns Engineering announces 3-Day Quick ... for the Food & Beverage, Pharmaceutical and Biotech markets. These ... ASME-BPE compliant and are now available as part of Burns’ ... , The S01 and S03 with 1/8” and ... process connections used in process lines 1/4” and larger. ...
    (Date:3/31/2015)... 31, 2015 The Heart Fit ... Calgary and surrounding areas. External Counterpulsation is an ... artery disease, specifically stable coronary artery disease. ... is used extensively all over the world for ... Calgarians (Albertans) are extremely fortunate to have the ...
    (Date:3/31/2015)... Orlando, FL (PRWEB) March 31, 2015 ... and Sickness Insurance programs, issues a travel advisory to ... Health care costs in the United States are higher ... than even in developed countries. For example, a ... while the same procedure costs about $34,358 . ...
    Breaking Medicine News(10 mins):Health News:Altima Adds More Hardware Devices to its NetZoom™ Visio® Stencils Device Library 2Health News:American Green Technology® Signs Exclusive Agreement to Distribute Health Risk Management System in Midwest 2Health News:Burns Engineering Now Offers 3-Day Quick Ship on Sanitary RTDs and Thermocouples 2Health News:New Heart Disease Treatment Called External Counterpulsation (EECP) helps people of Alberta Who Have Failed or Are Not Suitable For Heart Stents or Surgery 2Health News:India Network Foundation issues travel advisory to all US bound travelers on visitor health insurance requirements 2Health News:India Network Foundation issues travel advisory to all US bound travelers on visitor health insurance requirements 3
    ... is in the process of doing away with a commonly ... phase out the ‘Aropax’ brand of paroxetine and bring in ... used by about 49,000 New Zealanders. ,This move ... maintains that both drugs are the same, except for the ...
    ... Forest University Baptist Medical Center are helping to lead ... that will test 3,000 patients in an effort to ... patients. ,Though doctors have promoted the value of ... training has not been definitively established as safe in ...
    ... why we shed tears. But exactly what our tears are made ... study sheds some light on the complex design of tears. What ... made up of three distinct, microscopic layers. The middle, watery layer ... – is sandwiched between a layer of mucus and an outer ...
    ... is an alarming rise of gambling and gamblers in Britain. ... gambling and casinos then on vegetables and fruits. ... been spent on gambling in United Kingdom. Online gambling has ... time. ,The British medical Association (BMA) has expressed ...
    ... The death of a 47-year-old man who had worked for ... hundreds of ex-employees, who had also been exposed to toxic ... Thursday, prompting more than 500 protestors, who said he had ... roads and demand an autopsy to assess the possibility of ...
    ... Plc, Europe's pharmaceutical giant, is finalizing its plan of action, ... Gardasil, in a bid to establish the most effective vaccine ... conducted in the United States, will seek to evaluate the ... to two strains of the human papillomavirus. This virus is ...
    Cached Medicine News:Health News:New International Study to Test Exercise in Heart Failure Patients 2Health News:New International Study to Test Exercise in Heart Failure Patients 3Health News:Tears Reveal Some of Their Deepest Secrets to Researchers 2Health News:Tears Reveal Some of Their Deepest Secrets to Researchers 3Health News:Ex-workers Ask HLL to Accept Liability for Mercury Deaths 2
    View Mex-2 is designed for out-patient surgery, hospital rounds and house calls....
    It provides excellent illumination from an inexpensive platform and is mounted on the comfortable UltraLite headband....
    Headlight module is mounted on UltraLite Plus headband....
    ... rapid rise in intracranial ... intervention and continuous monitoring. ... technology that gets to ... Its versatility makes it ...
    Medicine Products: